Contribute Try STAT+ Today

Biogen’s unexpectedly successful new rare-disease drug, Spinraza, delivered another surprise in the first quarter: flat sales.

The drug, which treats spinal muscular atrophy, ran off to an impressive start last year, topping analyst estimates and beating even Biogen’s projections. But everything leveled off between the fourth quarter, when revenue hit $363 million, and the first three months of 2018, when Biogen booked $364 million in Spinraza sales. Analysts had expected first-quarter sales of about $383 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.